When I think about the phrase “patient-centricity,” I often pause. It’s everywhere in our industry: clinical trial brochures, conference panels, even corporate mission statements. But too often, it risks becoming a buzzword rather than a lived reality. In our...
TriNetX is proud to announce that we were named a Best of Show Finalist at SCOPE, the summit for clinical ops executives, one of the industry’s premier events focused on advancing clinical operations and innovation. This recognition highlights our continued commitment...
As we step into 2026, the biopharma industry finds itself at a different starting line than anyone predicted just a year ago. As Director of Content & Communication at TriNetX, I’ve watched which resources captivated our community in 2025, and more...
When every respondent in a survey agrees, it’s more than a trend; it’s a mandate. In the 2025 TriNetX and studioID survey of 150 senior biopharma executives, all participants agreed that real-world evidence (RWE) has the potential to improve regulatory submissions....
As 2025 wraps up, the TriNetX team is reflecting on a year of milestones, among them, being named to The Healthcare Technology Report’s Top 50 Healthcare Technology Companies list this November. Earlier this year, TriNetX was also recognized among the Top 25...
Chimeric antigen receptor (CAR) T-cell therapy is among the most promising breakthroughs in modern oncology. By genetically engineering a patient’s T lymphocytes to recognize and destroy cancer cells, CAR T-cell therapy has redefined what is possible in adoptive...
